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It is uncertain whether clinical severity of an infection varies by pathogen or by multiple infections. 
Using hospital‑based surveillance in children, we investigate the range of clinical severity for patients 
singly, multiply, and not infected with a group of commonly circulating viruses in Nha Trang, Vietnam. 
RT‑PCR was performed to detect 13 respiratory viruses in nasopharyngeal samples from enrolled 
patients. We apply a novel clinical severity score and examine associations with the odds of being 
severe and differences in raw severity scores. We find no difference in severity between 0‑, 1‑, and 
2‑concurrent infections and little differences in severity between specific viruses. We find RSV and 
HMPV infections to be associated with 2‑ and 1.5‑fold increase in odds of being severe, respectively, 
and that infection with ADV is consistently associated with lower risk of severity. Clinically, based on 
the results here, if RSV or HMPV virus is suspected, PCR testing for confirmatory diagnosis and for 
detection of multiple coinfecting viruses would be fruitful to assess whether a patient’s disease course 
is going to be severe.
Acute respiratory infections (ARIs) cause substantial morbidity and mortality across the globe, especially in 
those under 5 years of  age1. For a clinician, rapid identification of the potential clinical severity of an incoming 
patient becomes paramount, especially in resource-limited settings and high-volume health care facilities. Thus, 
with many different pathogens circulating within a community, it becomes important to understand what dif-
ferences exist in patient severity by infecting pathogen and by whether the patient is infected with one, two, or 
more viruses simultaneously. While several studies have examined the severity of single versus > 1 infections and 
found no differences in multiple severity indicators (as reviewed in Scotta et al.2, Lim et al.3, and Asner et al.4), 
little is known about potential differences in clinical severity across specific viruses in single versus multiply-
infected individuals.
Previous work is equivocal on the severity of respiratory syncytial virus (RSV) and human metapneumo virus 
(HMPV) coinfections. Some reports indicate increased severity in RSV and HMPV coinfected  individuals5–7, 
while others do  not8,9. Several studies have compared the severity of Influenza A (Flu A) and B (Flu B) coinfec-
tions: Goka et al.10 found increased hospitalization rates for Flu A/B coinfected individuals, while Rhedin et al.11 
found no increase in clinical severity for Flu A H1N1 coinfected individuals. Fewer studies have focused on the 
role of coinfection with other common, and less common respiratory viruses including adenovirus (ADV)12, 
human bocavirus (HBoV)13, human parainfluenza viruses (HPIV1-4)2, and human rhinovirus (HRV)14. Knowl-
edge of differing clinical severity of these pathogens in mono and multiply infected individuals is lacking.
Finally, most of the reports of virus-specific and coinfection severity have not been conducted in developing 
countries. A systematic review of multiple respiratory infections and severity thereof by Scotta et al. reported 
6 studies from China, 3 from Vietnam, and 1 each from Cambodia and  Madagascar2. Thus, it is the goal of the 
present study to explore indicators of clinical severity, including the role of specific viruses and 0, 1, and multiple 
concurrent infections, in a large cohort of hospitalized children in Nha Trang, Vietnam.
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Methods
Study site. The study site is Nha Trang, central Vietnam, where the study population has been described 
 previously15–17.The ongoing study was initiated as an active prospective surveillance study of respiratory illness 
in children under the age of 16 years in Nha Trang, enroll all hospitalized ARI cases from our target population. 
According to the field site census survey in July 2006, the study catchment area of 16 communes in Nha Trang 
city, had 198,729 residents including 13,952 children less than 5 years of age. We analyze data from January 29, 
2007 to April 26, 2012 at Khanh Hoa General Hospital (KHGH) which is the only tertiary care facility located in 
Khanh Hoa Province and the only one accessible for residents of the catchment area. An ARI case was defined as 
any child presenting to KHGH with cough or/and difficulty in breathing. Eligible children were under 16 years 
old and were enrolled at all times of the year. Clinical and demographic information, chest radiographs (CXR), 
laboratory data, and nasopharyngeal (NP) samples were collected from all enrolled patients. Radiographically-
confirmed pneumonia (RCP) was categorized using the WHO standard case  definition18. In 2013 all CXRs 
were re-read independently by two designated radiologists. An expert panel reviewed discordant readings and 
a sample of concurrent readings. Acute respiratory infection patients with normal CXR were categorized as 
upper respiratory tract infection (URTI). Patients with abnormal CXR were categorized as lower respiratory 
tract infection (LRTI).
Laboratory methods have been previously  described16. NP swabs were collected at the time of admission and 
viral nucleic acid was extracted using QIA viral RNA minikit (QIAGEN Inc., Valencia, CA). Four multiplex-
PCR assays (1: influenza A, influenza B, RSV, hMPV; 2: HPIV-1, -2, -3, and -4; 3: rhinovirus, coronavirus 229E, 
coronavirus OC43; 4: adenovirus and bocavirus) were performed to detect 13 respiratory viruses in each NP 
sample. A second confirmatory-PCR was performed for samples positive on the initial PCR test. Samples positive 
for both PCR assays were defined as positive. The samples were screened for 13 respiratory viruses using four 
multiplex PCR assays. The positive PCR product will be used to conduct a second PCR (heminested PCR) with 
inner primers targeting the respective gene of the virus. This two step screening and confirmation can detect 
target respiratory viruses with 1000–10,000 copies per reaction. The assay has a high specificity that only less 
than 1% of the samples positive in first assay will be negative with the second nested confirmatory PCR.
Ethics, consent and permissions. The authors assert that all of the procedures contributing to this work 
comply with the ethical standards of the relevant national and institutional committees on human experimenta-
tion and the Helsinki Declaration of 1975 as revised in 2008. Before study enrollment, informed consent was 
obtained from parents of children who presented with ARI and lived in the study catchment area. The study was 
approved by institutional review boards in the National Institute of Hygiene and Epidemiology, Vietnam and the 
Institute of Tropical Medicine, Nagasaki University, Japan.
Indicators of clinical severity. We modified a clinical severity score (CSS) developed  previously19,20 to 
include additional variables collected in our study. The original CSS gave 2 points if the child required mechani-
cal ventilation during their hospitalization, and 1 point for each of the following: hospital admission (all chil-
dren), hospitalization for 5 or more days, oxygen saturation less than 87%, and use of supplemental oxygen. In 
addition to this, we add 1 point each if the child has chest indrawing, wheezing, tachypnea, or difficulty breath-
ing. Our score ranges from 0 to 10. We define severe respiratory disease as children with CSS > 3 . We explore 
cutoffs of 2 and 4 in the supplementary material. In addition, wheezing has been associated with less severe LRTI 
in children without danger signs such as chest indrawing or  malnutrition21 and equivocally with RSV  infection22, 
thus in the supplement we explore the associations between virus detections and wheezing and present results of 
the risk score without wheezing. The CSS was calculated once for each child retroactively with scores calculated 
with data from the entire hospital stay. Future studies should calculate the score upon admission.
Statistical analysis. We compare the CSS across viruses using means and interquartile ranges (IQR) and 
calculate multinomial confidence intervals using the method of Sison and  Graz23, as implemented in the R 
package MultinomialCI24. We use one- and two-sided proportion tests to compare the proportion of severe 
disease by virus and mono-, multiply-infected, and PCR negative patients and Wilcoxon signed rank tests to 
compare raw CSS. Logistic regression models were formed with severe disease (CSS > 3 ) as the outcome and the 
individual virus as the predictor. We fit single logistic regressions for each virus and multiple logistic regressions 
to adjust for age, sex, smoking inside the child’s home, socioeconomic status (SES), calendar year, month of year, 
daycare attendance, and breastfeeding status. We also form logistic regressions to compare the odds of severe 
disease by number of viruses detected (0, 1, 2, ≥ 3 ). To compare the differences in CSS between viruses, we 
formulate single linear regressions and multiple linear regressions (adjusted for the variables listed above) with 
CSS score as the outcome and the presence/absence of each virus as a predictor. All analyses were conducted in 
R 3.3.125
Sensitivity analyses. Sensitivity analyses, presented in the supplementary materials, include changing the 
CSS cutoff for classifying a patient as severe to > 2 and > 4 , as well as Bayesian logistic regressions to account 
for potential sparse data  biases26, and examination of severity in children with no known underlying conditions.
Results
Predictors of severity. The study enrolled 3431 children between 2007 and 2013. Among those, 28 did not 
have clinical samples or RCP screen and were excluded from the analyses, thus the total study population was 
3403. The age of hospitalized children ranged from 14 days to 15 years, with a median of 17 months (interquar-
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tile range [IQR]: 9, 28). Number of virus detections ranged from 0 to 4 detections (Table 1; Fig. 1). CSS scores 
were generally low, the vast majority of CSS were 1 and 2 (2271 of 3403, 67%), though 33% (1132 of 3403) were 
classified as severe cases (CSS > 3 ), and 285 patients (8.4%) had scores over 5. Multivariate logistic regression 
showed male sex (OR 1.36 [95% CI 1.1, 1.7, p = 0.005 ) as a positive predictor of clinical severity (Table 2). No 
association was found between RCP and odds of being classified as a severe case (OR 1.35 [95% CI 0.84, 2.08, 
p = 0.191]). RCP was significantly associated with a higher raw CSS (2.64 [95% CI 2.43, 2.84] vs. 2.29 [95% CI 
2.25, 2.33]; Wilcoxon signed rank: p < 0.001 ). Small, but significant differences in CSS were seen between 0–12, 
12–24, and over 24 months of age (2.47 [95% CI 2.39, 2.54], 2.3 [95% CI 2.23, 2.38], and 2.15 [95% CI 2.08, 2.22] 
vs. 2.01 [95% CI 1.89, 2.13]; Kruskal–Wallis rank sum test, p < 0.001).
Severity across viruses. CSS ranged from a mean of 1.83 (IQR 1, 2) for HRV to 2.74 (IQR 2, 3) for Flu A 
(Fig. 2). Tables 3 and 4 show model estimates of the odds of being a severe case by each virus and the relative 
contribution of each virus to the CSS, respectively. After adjusting for various potential confounding variables, 
HMPV and RSV infection were 2.13 (95% CI 1.28, 3.44, p = 0.003 ) and 1.47 (95% CI 1.1, 1.95, p = 0.009 ) times 
more likely to be severe infections than other viruses, respectively. ADV on the other hand was associated with 
55% (OR: 0.45 [95% CI 0.26, 0.73, p = 0.003 ]) lower risk of being a severe case. The other viruses were not indi-
vidually associated with being a severe case. Sensitivity analyses with higher and lower cutoff for severity showed 
qualitatively similar trends, with ADV associated with lower odds of severity, and HMPV, HPIV3, and RSV with 
higher odds of severity (see Supplementary Tables 1 & 2). Flu A was negatively associated with wheezing (OR 
0.68, 95% CI 0.53, 0.86, p = 0.001), while HMPV, HPIV3, and RSV were positively associated with wheezing 
(OR 1.85, 95% CI 1.17, 2.96, p = 0.009; 2.11, 95% CI 1.34, 3.34, p = 0.001; 1.63, 95% CI 1.31, 2.04, p < 0.001; see 
Supplementary Tables 3 and 4). Assessing severity across viruses without wheezing were similar to the main 
analyses with HMPV and RSV being associated with higher odds of being severe (OR 1.83, 95% CI 0.95, 3.27, p 
= 0.05; 1.82, 95% CI 1.29, 2.56, p < 0.001).
HMPV, HPIV3, and RSV were associated with higher CSS scores, with an additional 0.47 points (95% CI 
0.22, 0.72, p < 0.001 ), 0.31 points (95% CI 0.06, 0.56, p = 0.016 ), and 0.3 (95% CI 0.18, 0.43, p < 0.001 ), respec-
tively. As above, ADV was associated with 0.2 fewer points (− 0.2, [95% CI − 0.38, − 0.02, p = 0.033]); as was 
Flu B, − 0.28 (95% CI − 0.55, 0.0, p = 0.05 ). No other viruses were associated with additional or fewer points.
Severity in coinfections. In general, individuals with single and multiple viral detections had similar 
proportions of severe cases (0.13 [95% CI 0.1, 0.17] and 0.15 [95% CI 0.14, 0.17], two-sided proportion test: 
p = 0.32 ) and mean CSS (2.37 (95% CI 2.3, 2.43) and 2.31 (95% CI 2.18, 2.44), Wilcoxon signed rank: p = 0.61 ). 
Comparing individuals with no detections to individuals with multiple detections, we see nearly identical pro-
portions of severe cases, with 0.13 [95% CI 0.098, 0.169] and 0.136 [95% CI 0.118, 0.156] of PCR negatives and 
multiple PCR positives severe, respectively; and no difference in mean CSS score (2.23 [95% CI 2.17, 2.3] and 
2.31 [95% CI 2.18, 2.44],Wilcoxon signed rank: p = 0.14)). PCR negative individuals did not have a smaller 
proportion of severe cases than individuals with one PCR detection (0.14 [95% CI 0.12, 0.16] vs. 0.15 [95% CI 
0.14, 0.17], two-sided proportion test: p = 0.22 ), and one PCR detection had a higher CSS (2.37 [95% CI 2.3, 
2.43] vs. 2.23 [95% CI 2.17, 2.3]; Wilcoxon signed rank: p = 0.001 ), which may or may not have clinical sig-
nificance. We do see higher odds of severity and CSS score in individuals with at least 3 detections with nearly 
3-fold higher adjusted OR of being severe (OR 2.65 [95% CI 1.17, 5.57, p = 0.013]) and 0.51 (95% CI 0.1, 0.92, 
p = 0.016) higher CSS scores. However, due to the small numbers of patients with ≥ 3 concurrent detections, 
we test for sparse data bias using Bayesian logistic regressions with informative priors. We find a diminishing 
of both the effect size and statistical significance (OR 1.63; 95% credible interval: 0.85, 2.97, p = 0.05), though 
the effect is still suggestive of these infections being more severe (see Supplementary Table 5 and Figures S1 and 
S2). Findings in children with no underlying conditions are qualitatively similar to those presented here (Sup-
plementary Table 6).
Examination of proportions of severity by number of PCR detections by individual viruses shows similar 
patterns across viruses (Fig. 3). There are no statistically significant differences in the proportion of severe indi-
viduals in mono- or multiply-infected individuals by virus or in PCR negative individuals.
Though not statistically significant, individuals with Flu B coinfections were more severe than mono-infected 
Flu B individuals (0.18 [95% CI 0.04, 0.43] vs. 0.08 [95% CI 0.03, 0.17]; one-sided proportion test: p = 0.07 ) and 
Table 1.  Numbers of virus detections by age. Table gives the numbers of virus detections (0–4) by age for the 
study population. Percents are percents of age class by number of detection, ie, 175 of 465 0–6 month olds 
(37.8%) had 0 detections.
Age
Detections (% by age)
0 1 2 3 4 Total
0–6 months 175 (37.8%) 246 (53.1%) 39 (8.4%) 3 (0.6%) 0 (0%) 465
6 months–1 year 390 (34.3%) 578 (50.9%) 147 (12.9%) 19 (1.7%) 2 (0.2%) 1138
1–2 year 361 (41.5%) 429 (49.4%) 70 (8.1%) 7 (0.8%) 2 (0.2%) 871
2–5 year 115 (49.4%) 115 (49.4%) 3 (1.3%) 0 (0%) 0 (0%) 233
5 year+ 275 (39.6%) 343 (49.4%) 67 (9.7%) 9 (1.3%) 0 (0%) 696
Total 1316 (38.7%) 1711 (50.3%) 326 (9.6%) 38 (1.1%) 4 (0.1%) 3403
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PCR negative individuals (0.29 [0.08, 0.58] and 0.13 [0.11, 0.15]; one-sided proportion test: p = 0.09 ). Mean CSS 
scores were similar between Flu B coinfections, monoinfections, and PCR negative individuals (2.29 [95% CI 1.34, 
3.23], 1.8 [95% CI 1.5, 2.09]], and 2.2 [95% CI 2.12, 2.28], respectively). While the proportion of severe cases is 
similar for single and coinfections with ADV (0.07 [95% CI 0.02, 0.17] and 0.05 [95% CI 0.02, 0.12]; two-sided 
proportion test: p = 0.98 ), the proportion of severe cases in mono- or coinfected ADV is lower than PCR nega-
tive individuals (0.05 [95% CI 0.02, 0.12] and 0.13 [95% CI 0.11, 0.15]; one-sided proportion test: p = 0.026).
Finally, comparing the proportion of severe cases virus to virus, we see ADV as consistently having lower 
proportions of severe cases as compared to the other viruses, and HMPV and RSV as consistently having higher 
proportions of severe cases (Fig. 4).
Discussion
Here we investigate the range of clinical severity for patients singly, multiply and not infected with a group of 13 
commonly circulating viruses in Nha Trang, Vietnam. Largely we find no difference in severity by multiplicity 
of viral infections and little differences in clinical severity between patients carrying different viruses. Of note, 
there is suggestion that infection with more than 2 viruses is more severe than infection with 0, 1, or 2 viruses. 
Figure 1.  Demographics of the study cohort. Figure shows the demographics of the cohort. Underlying 
conditions of chronic diarrhea, cardiac, neurological, renal, malnourished, and thalassemia had less than 
5% prevalences each. Similarly with discharges of rhinitis, pharyngitis, tonsillitis, otitis media, croup, trach, 
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Also, detection of HMPV and RSV—either as as monoinfection or as part of a coinfection—was associated with 
increased risk of being severe, this association being robust to inclusion of wheezing. Finally, we find infection 
with ADV to be consistently associated with lower risk of severity. While clinically it is difficult or impossible to 
distinguish between the various infecting pathogen, if RSV or HMPV virus is suspected, PCR testing for con-
firmatory diagnosis and for detection of multiple coinfecting viruses would be fruitful to assess the probability of 
whether the patient’s disease course is going to be severe. If PCR testing reveals the presence of the other viruses, 
however, the clinician may expect a less severe clinical course.
Previous work has found increased severity with RSV and HMPV coinfection. Semple et al.6 found dual 
infection with RSV and HMPV (as detected using NP aspirate) to be strongly associated with 11-fold higher 
risk of admission to the pediatric intensive care unit as compared to RSV monoinfection, but a non-significant 
increase in risk of severe disease (defined as admission to the hospital and use of supplemental oxygen). Of our 
3403 enrolled patients only 2 had RSV/HMPV coinfection, 1 of which had a CSS of 5. Using data from the same 
study site but limited to April 2007 through to March 2010, Yoshida et al.5 found RSV to be the leading patho-
gen associated with ARI hospitalization and RSV and HMPV to be associated with LRTI. Harada et al.27 found 
2.95- and 2.4-fold increases in odds of nonpneumonic ARI and RCP as compared to mild disease, respectively, 
in individuals positive for RSV either singly or as part of a coinfection, and a nearly 5-fold increase in odds of 
nonpneumonic ARI vs. mild disease in coinfected RSV individuals. We consistently found RSV to be associated 
with higher odds of severity and CSS.
Several studies have indicated that the clinical symptoms and severity of HMPV infections are similar to that 
of  RSV8,9,28,29. Indeed, both viruses are of the family Paramyxoviridae and recent work has identified cross-reactive 
neutralizing antibodies to the fusion proteins of both HMPV and  RSV30–32. While we find a higher proportion 
of severe cases in HMPV vs. RSV infected individuals (0.24 vs. 0.17, p = 0.04 ), we find no statistical difference 
between the odds of severe disease or raw CSS, though the point estimates suggest HMPV may be more severe. 
Future work could further examine differences in HMPV and RSV cases.
Surprisingly, we find a reduced severity with ADV infection as compared to the other viruses in our study. 
ADV infection severity is under-explored and open questions remain about the role of ADV coinfection and 
clinical  severity12. Martin et al.33 found over 50% of 103 identified coinfected samples tested positive for ADV 
and that ADV coinfections had a significantly lower viral load than ADV monoinfections. ADV is often carried 
asymptomatically and may have persistent viral  shedding34,35, perhaps individuals admitted for ARI had some 
other etiology than the present ADV infection. It is known that different ADV types are associated with different 
clinical  severity36,37. For example, the 9 identified ADV types in a cohort of Korean children varied in clinical 
severity from 0 severe cases for ADV-4 and -6 to 23 (25%) for ADV-736. As we do not have information on ADV 
type in our hospitalized patients, it may be that dominant type in Southern Vietnam is less severe. These serotype 
differences may also explain the results of Mazur et al.38 which found 3.4-fold increase in the odds of severe 
disease for ADV coinfections. Identification of the circulating ADV types in Vietnam would further elucidate 
our observed patterns.
Recent meta-analyses have found no increased severity in ARI for coinfected  individuals2–4. We find a sug-
gestion of increased severity only in individuals with 3 or more detections. While this outcome was rare (42 
individuals, 1.2%), it may be that the presence of 3 or more viruses puts added pressure on the immune system 
resulting in a more intense response, or perhaps those children had underlying conditions to predispose them 
to multiple coinfections. We acknowledge that this finding cannot be ruled out that this result is a statistical 
artifact due to small data bias, though the point estimate is for it being more severe. Future work could more 
fully evaluate these multiply-infected individuals for salient features of severity, and evaluation of individuals in 
other settings would help explore this finding more.
Due to the nature of the study we are not able to determine the order of infection for coinfected individuals. 
Longitudinal study of a cohort of individuals with multiple NP swabs taken over time would allow understanding 
Table 2.  Predictors of clinical severity. Table gives the adjusted odds ratios of being a severe clinical case (CSS 
> 3 ) by coinfection status (more than 1 detection), RCP (yes/no), per year of age, Male sex (male vs. female), 
smoking in the home (yes/no), attending daycare (yes/no), breastfeeding status (yes/no), and socioeconomic 
status (SES; low and middle vs. high). The model is additionally adjusted for calendar year and month of year. 
Estimates displayed in bold face indicate statistical significance (p<0.05).
Predictor Multivariate OR (95% CI, p)
Coinfection 1.01 (0.72, 1.41, p = 0.932)
RCP 1.35 (0.84, 2.08, p = 0.191)
Age 1.16 (0.54, 2.35, p = 0.697)
Male 1.36 (1.1, 1.69, p = 0.005)
Smoke inside 0.97 (0.86, 1.08, p = 0.557)
Daycare 0.83 (0.65, 1.05, p = 0.124)
Breastfeeding 1.07 (0.83, 1.39, p = 0.602)
Low SES 1.08 (0.83, 1.4, p = 0.58)
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of the temporal interaction of these respiratory viruses. It would be interesting to see if infection with RSV or 
HMPV modifies future infection risk from other viruses. Further limitations of the present study include the fact 
that this study used hospital-based surveillance, necessarily presenting the most ill children which may have dif-
fering underlying risk for having severe disease. In addition, this study does not allow comparison with outpatient 
severity. However our focus was on elucidating the potential severity of children hospitalized for ARI. And, by 
the time the individual is hospitalized, a pathogen may have been cleared, and not detected in the NP swab. It 
Figure 2.  Distribution of CSS by virus. Figure shows the distributions (counts) of CSS by virus. Multinomial 
confidence intervals are calculated using the method of Sison and  Graz23, as implemented in the R package 
MultinomialCI24. ADV Adenovirus, HBoV Human bocavirus, HMPV Human metapneumoviruses, HPIV-
1, -2, -3, -4 Human parainfluenza viruses 1–4, HRV Human rhinovirus, Flu A influenza A, Flu B influenza B, 
RSV Respiratory syncytial virus.
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may be that infection with one pathogen enhanced the severity of a subsequent infection leading to hospitaliza-
tion with the first infection cleared. We are unable to detect enhancing infections of this type, and hence may 
under-estimate the clinical role of viral co-infection. We do not have information on subsequent admission to the 
Table 3.  Clinical severity by virus and number of detections. Table shows counts of hospitalizations with 
detections of Adenovirus (ADV), Bocavirus (HBoV), Human metapneumovirus (HMPV), H. parainfluenza 
1 (HPIV1), H. parainfluenza 2 (HPIV2), H. parainfluenza 3 (HPIV3), Influenza A, Influenza B, Rhinovirus 
(HRV), and Respiratory syntitial virus (RSV), with the number of severe cases (defined as CSS > 3 ) for each 
virus. HPIV4 and H. coronavirus had no severe cases. The final two columns show the odds ratio for being a 
severe case (both mono- and coinfected) for the univariate model (virus only) as well as the multivariate model 
(adjusted for age, sex, smoking inside the child’s home, SES, calendar year, month of year, daycare attendance, 
and breastfeeding status). The comparator is all other cases without the focal virus. The bottom part of the table 
shows contributions to CSS by 1, 2, or ≥ 3 virus detections as compared to PCR negative patients. Estimates 
displayed in bold face indicate statistical significance (p<0.05).
Total detections Severe cases (%) Univariate OR (95% CI, p) Multivariate OR (95% CI, p)
ADV 219 16 (7.3%) 0.45 (0.26, 0.73, p = 0.003) 0.43 (0.23, 0.76, p = 0.007)
HBoV 64 10 (15.6%) 1.11 (0.53, 2.09, p = 0.773) 1.15 (0.54, 2.25, p = 0.697)
HMPV 95 23 (24.2%) 1.95 (1.18, 3.1, p = 0.006) 2.13 (1.28, 3.44, p = 0.003)
HPIV1 56 7 (12.5%) 0.85 (0.35, 1.76, p = 0.687) 0.74 (0.25, 1.72, p = 0.527)
HPIV2 18 2 (11.1%) 0.74 (0.12, 2.62, p = 0.693) 0.82 (0.13, 3.02, p = 0.794)
HPIV3 100 20 (20%) 1.51 (0.89, 2.44, p = 0.106) 1.51 (0.86, 2.53, p = 0.133)
HRV 819 126 (15.4%) 1.11 (0.89, 1.38, p = 0.344) 1.09 (0.85, 1.38, p = 0.487)
Flu A 390 48 (12.3%) 0.82 (0.59, 1.11, p = 0.217) 0.81 (0.57, 1.12, p = 0.211)
Flu B 83 8 (9.6%) 0.63 (0.28, 1.23, p = 0.217) 0.85 (0.37, 1.7, p = 0.662)
RSV 633 106 (16.7%) 1.25 (0.99, 1.58, p = 0.06) 1.47 (1.1, 1.95, p = 0.009)
PCR Neg. 1316 179 (13.6%) Ref. Ref.
1 detection 1711 261 (15.3%) 1.22 (1.04, 1.42, p = 0.012) 1.13 (0.91, 1.42, p = 0.273)
2 detections 326 38 (11.7%) 1.15 (0.88, 1.48, p = 0.301) 0.94 (0.62, 1.38, p = 0.757)
≥ 3 detections 42 10 (23.8%) 1.25 (0.64, 2.34, p = 0.496) 2.65 (1.17, 5.57, p = 0.013)
Table 4.  Contributions to CSS by virus and number of virus detections. Table shows differences in CSS 
by virus detected estimated by regression with CSS as the outcome with viral detections as predictors. The 
first column is univariate (virus only) model, the second is the multivariate model (adjusted for age, sex, 
smoking inside the child’s home, SES, calendar year, month of year, daycare attendance, and breastfeeding 
status). For example, HMPV is associated with 0.51 (95% CI 0.22, 0.80, p < 0.001 ) higher CSS adjusted for 
the confounders. The bottom part of the table shows contributions to CSS by 1, 2, or ≥ 3 virus detections 
as compared to PCR negative patients. ADV Adenovirus, HBoV Human bocavirus, HMPV Human 
metapneumoviruses, HPIV-1, -2, -3, -4 Human parainfluenza viruses 1–4, HRV Human rhinovirus, Flu A 
influenza A, Flu B influenza B, RSV respiratory syncytial virus. Estimates displayed in bold face indicate 
statistical significance (p<0.05).
Univariate Change in CSS (95% CI) Multivariate Change in CSS (95% CI)
ADV − 0.27 (95% CI: − 0.45, − 0.1, p = 0.002) − 0.2 (95% CI: − 0.38, − 0.02, p = 0.033)
HBoV − 0.08 (95% CI: − 0.39, 0.24, p = 0.64) 0 (95% CI: − 0.33, 0.33, p = 0.997)
HMPV 0.44 (95% CI: 0.18, 0.7, p < 0.001) 0.47 (95% CI: 0.22, 0.72, p < 0.001)
HPIV1 − 0.1 (95% CI: − 0.43, 0.24, p = 0.579) − 0.06 (95% CI: − 0.41, 0.28, p = 0.711)
HPIV2 − 0.09 (95% CI: − 0.68, 0.51, p = 0.774) 0.01 (95% CI: − 0.59, 0.62, p = 0.966)
HPIV3 0.28 (95% CI: 0.02, 0.53, p = 0.032) 0.31 (95% CI: 0.06, 0.56, p = 0.016)
HPIV4 − 0.31 (95% CI: − 1.57, 0.95, p = 0.63) 0.14 (95% CI: − 1.25, 1.53, p = 0.842)
HRV 0.06 (95% CI: − 0.04, 0.16, p = 0.245) 0.03 (95% CI: − 0.07, 0.14, p = 0.534)
Flu A − 0.11 (95% CI: − 0.25, 0.02, p = 0.098) − 0.12 (95% CI: − 0.25, 0.02, p = 0.086)
Flu B − 0.49 (95% CI: − 0.77, − 0.21, p < 0.001) − 0.28 (95% CI: − 0.55, 0, p = 0.05)
RSV 0.29 (95% CI: 0.18, 0.4, p < 0.001) 0.3 (95% CI: 0.18, 0.42, p < 0.001)
PCR Neg. Ref. Ref.
1 detection 0.13 (0.04, 0.22, p = 0.0055) 0.11 (0.01, 0.2, p = 0.0243)
2 detections 0.04 (− 0.11, 0.2, p = 0.5759) 0.07 (− 0.09, 0.23, p = 0.3814)
≥ 3 detections 0.31 (− 0.08, 0.71, p = 0.1194) 0.51 (0.1, 0.92, p = 0.0157)
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pediatric intensive care unit, nor use of high flow nasal cannula or continuous positive airway pressure support 
in the pediatric intensive care unit. Subsequent studies should include these indicators as early prediction of use 
of these medically serious and expensive outcomes would be beneficial to clinical care. We acknowledge that in 
clinical practice it is not uncommon to identify infants with bronchiolitis and normal chest X rays. It is why we 
have other clinical parameters in the scoring system and our main outcome was being a severe case not a positive 
chest X ray. Although we have not adjusted for multiple testing here, ours is an exploratory study to identify risk 
factors for severity which will require future work to elucidate. In addition our main study conclusions are robust 
to multiple cutoffs defining our main endpoint as well as in a Bayesian regression setting. Finally, we are not 
considering bacterial agents as the potential etiology of hospital admissions. It may be that observed similarities 
in severity across viruses is an indication that viral detection has little to do with the disease episode and that 
other etiologies are at play. Future work should explore the role of bacteria in disease etiologies in this setting.
Our work identifies risk of severe outcomes by specific viruses in hospitalized individuals and lends to the 
suggestion of PCR screening individuals as they enter the hospital. Future work could build on these observed 
patterns and test specific mechanisms for differences in disease severity. It could also examine risk of coinfec-
tion from contact  clustering39,40, or the impact of environmental factors on disease risk. Our study provides 
evidence that while in some cases multiple viral infection may provide a perfect storm causing serious disease, 
viral coinfection as a cause of mild or severe ARI is generally uncommon both in its absolute frequency and in 
its risk enhancement for severe disease compared to a single virus infection.
Figure 3.  Percent of patients with severe disease by virus for no-, mono-, and multiple-infections and percent 
of severe and non-severe cases by virus and number of viruses detected in the NP sample. Panel (A) shows 
the percent of patients suffering severe disease (CSS > 3 ) by virus and whether the patient was PCR negative 
(dashed black line), PCR positive for 1 virus (light blue), or PCR positive for more than 1 virus (dark blue). 
Line segments indicate 95% binomial confidence intervals. Panel (B) show the percent of severe and non-
severe patients by virus and PCR positive for 1, 2, or ≥ 3 viruses, respectively. ADV Adenovirus, HBoV Human 
bocavirus, HMPVHuman metapneumoviruses, HPIV-1, -2, -3, -4 Human parainfluenza viruses 1–4, HRV 
Human rhinovirus, Flu A influenza A, Flu B influenza B, RSV respiratory syncytial virus.
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